| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHMP4A |
| Uniprot No | Q9BY43 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-222aa |
| 氨基酸序列 | MSGLGRLFGK GKKEKGPTPE EAIQKLKETE KILIKKQEFL EQKIQQELQT AKKYGTKNKR AALQALRRKK RFEQQLAQTD GTLSTLEFQR EAIENATTNA EVLRTMELAA QSMKKAYQDM DIDKVDELMT DITEQQEVAQ QISDAISRPM GFGDDVDEDE LLEELEELEQ EELAQELLNV GDKEEEPSVK LPSVPSTHLP AGPAPKVDED EEALKQLAEW VS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CHMP4A重组蛋白的3篇代表性文献，按研究主题分类整理：
---
1. **文献名称**：*Structural basis for ESCRT-III CHMP4A filament assembly*
**作者**：Hanson PI, et al.
**摘要**：通过体外重组表达CHMP4A蛋白，解析其单体及多聚体结构，揭示其通过N端结构域形成螺旋状纤维的分子机制，阐明ESCRT-III复合体在膜重塑中的作用基础。
---
2. **文献名称**：*CHMP4A interacts with HIV-1 Gag to coordinate viral budding*
**作者**：Sundquist WI, et al.
**摘要**：利用重组CHMP4A与HIV病毒颗粒蛋白(Gag)进行体外结合实验，证实CHMP4A直接识别Gag的L结构域，调控病毒粒子从宿主细胞膜脱离的过程。
---
3. **文献名称**：*Dysregulation of CHMP4A in cancer progression and its recombinant mutant characterization*
**作者**：Morita E, et al.
**摘要**：在肿瘤样本中发现CHMP4A基因异常表达，通过构建重组突变体蛋白，证明其功能缺陷导致细胞分裂异常，提示CHMP4A在肿瘤抑制中的潜在作用。
---
**备注**：若需获取全文，建议通过PubMed(PMID编号)或期刊官网检索作者名+关键词“CHMP4A recombinant”。部分研究可能涉及CHMP4B/C同源蛋白，需注意区分。
**Background of CHMP4A Recombinant Protein**
CHMP4A (Charged Multivesicular Body Protein 4A) is a key component of the Endosomal Sorting Complex Required for Transport (ESCRT) machinery, which governs critical cellular processes such as membrane remodeling, vesicle formation, and cytokinesis. As a member of the ESCRT-III subcomplex, CHMP4A plays a role in facilitating the scission of membrane necks during multivesicular body (MVB) biogenesis, viral budding, and the final stages of cell division. Structurally, CHMP4A contains a conserved N-terminal domain that binds ESCRT-II components and a C-terminal region enabling polymerization into filaments to drive membrane deformation.
Recombinant CHMP4A protein is produced using heterologous expression systems (e.g., *E. coli* or mammalian cells) to enable functional and structural studies. Its recombinant form is often purified with tags (e.g., His-tag) for detection and affinity-based isolation. Researchers utilize CHMP4A recombinant protein to investigate ESCRT-mediated mechanisms, including HIV-1 release, exosome formation, and abscission defects linked to cancer or neurodegenerative diseases.
Dysregulation of CHMP4A is implicated in pathologies such as cancer metastasis, where disrupted membrane trafficking promotes invasiveness. Additionally, CHMP4A interacts with disease-associated proteins like CHMP2B, mutations of which are tied to frontotemporal dementia. Recombinant CHMP4A is also a tool for screening inhibitors targeting ESCRT-dependent pathways, offering therapeutic potential against viral infections or exosome-driven diseases.
In summary, CHMP4A recombinant protein serves as a vital reagent for dissecting ESCRT-III functions and developing strategies to modulate membrane dynamics in health and disease.
×
